ALK and cancer: A NGS analysis to the FFPE specimen using a 76 cancer-related gene panel (DNA-based detection, Amoy Diagnostics, Xiamen, China) revealed a double ALK fusion: EML4-ALK ARID2-ALK (E20:A20, 0.99% abundance; and A12:A23, 1.67% abundance) (Fig. 4 C), which was confirmed by another NGS 10 cancer‐related gene panel (RNA-based detection for fusion genes, Amoy Diagnostics, Xiamen, China), the results also showed a double ALK fusion: EML4-ALK ARID2-ALK (E20:A20, 0.81% abundance; and A12:A23, 1.09% abundance) (Fig. 4D).